Bayer AG NA (BAYN HM) stock market data APIs
€26.398
0.84(3.2%)
as of June 20, 2025
Try our APIs with
free plan!
Bayer AG NA Financial Data Overview
There is no Profile data available for BAYN.HM.
Prev. Close
26.398
Open
27.24
High
27.0288
Low
26.398
52 wk Range
18.605-30.6832
Market Cap
45 791 M
EPS
1.22
Dividends (Yield)
0.0497
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bayer AG NA data using free add-ons & libraries
Get Bayer AG NA Fundamental Data
Bayer AG NA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-08
- EPS/Forecast: 1.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bayer AG NA News
New
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. The regulatory body approved lenacapavir, under the br...
Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane
Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, ...
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
Shares of Incyte INCY gained 5.1% on Monday following the announcement of a global partnership with Netherlands-based QIAGEN N.V. QGEN. The collaboration aims to develop a novel diagnostic panel to su...
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
Teva Pharmaceutical TEVA announced that it has entered into a strategic collaboration agreement with China-based Fosun Pharmaceutical to codevelop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. TEV-5...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
